CalciMedica Files Proxy Statement for August Shareholder Meeting

TL;DR

CalciMedica proxy filed for Aug 27 meeting - vote your shares!

AI Summary

CalciMedica, Inc. filed its definitive proxy statement on July 16, 2024, for its annual meeting of stockholders scheduled for August 27, 2024. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership and proposals, enabling informed voting decisions that can impact the company's strategic direction and governance.

Risk Assessment

Risk Level: low — This is a routine proxy filing, providing information to shareholders for an upcoming meeting, and does not contain new material financial or operational news.

Key Players & Entities

• CalciMedica, Inc. (company) — Registrant
• 20240827 (date) — Annual Meeting Date
• 20240716 (date) — Filing Date

FAQ

Filing Documents

• d34221ddef14a.htm (DEF 14A) — 659KB
• g34221g0712025538855.jpg (GRAPHIC) — 2KB
• g34221g11c01.jpg (GRAPHIC) — 273KB
• g34221g11c02.jpg (GRAPHIC) — 118KB
• 0001193125-24-179344.txt ( ) — 1191KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 34 EXECUTIVE OFFICERS 37

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 39 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS 47 ADDITIONAL INFORMATION 52 OTHER MATTERS 53 APPENDIX A A-1 Table of Contents EXPLANATORY NOTE On March 20, 2023, the Delaware corporation formerly known as Graybug Vision, Inc. completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended on February 10, 2023 (the Merger Agreement), by and among Graybug Vision, Inc. (Graybug), Camaro Merger Sub, Inc., a wholly owned subsidiary of Graybug (Merger Sub), and CalciMedica, Inc. (Private CalciMedica), pursuant to which Merger Sub merged with and into Private CalciMedica, with Private CalciMedica surviving the merger as a wholly owned subsidiary of Graybug (the Merger). Additionally, on March 20, 2023, the Company changed its name from Graybug Vision, Inc. to CalciMedica, Inc. (the Company). In this Proxy Statement, unless the context indicates otherwise, the terms Company, we, us, and our refer to (i) Graybug Vision, Inc., for periods prior to the effectiveness of the Merger and (ii) CalciMedica, Inc. for periods following the effectiveness of the Merger, and the term Private CalciMedica refers to CalciMedica, Inc. prior to the effectiveness of the Merger. On March 17, 2023, in connection with the transactions contemplated by the Merger Agreement, we filed an Amended and Restated Certificate of Incorporation effecting a reverse stock split of our common stock at a ratio of 14:1 (the Reverse Stock Split). As a result of the Reverse Stock Split, the number of issued and outstanding shares of our common stock immediately prior to the Reverse Stock Split was reduced into a smaller number of shares, such that every 14 shares of our common stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share of common stock after the Reverse

forward-looking statements by terms such as aim, may, will, should, expect, believe, plan, anticipate, could, intend,

forward-looking statements by terms such as aim, may, will, should, expect, believe, plan, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, potential, seeks, or continue or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

Forward-looking statements are based upon various estimates

Forward-looking statements are based upon various estimates and assumptions, as well as information known to us as of the date hereof and are subject to risks and uncertainties. Accordingly, actual results could differ materially due to a variety of factors. These risks and uncertainties include, but are not limited to, those described under the caption Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023 (Annual Report), as updated by our subsequent quarterly reports and our other Securities and Exchange Commission (SEC) filings, which are available on the Investor Relations page of our website at https://ir.calcimedica.com and on the SEC website at www.sec.gov. All forward-looking statements contained herein are based on information available to us as of the date hereof and you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance, or achievements. We undertake no obligation to update any of these forward-looking statements for any reason after the date of this Proxy Statement or to conform these statements to actual results or revised expectations, except as required by law. Undue reliance should not be placed on forward-looking statements. 5 Table of Contents CALCIMEDICA, INC. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 27, 2024 INFORMATION ABOUT SOLICITATION AND VOTING The accompanying proxy is solicited on behalf of the Board of Directors of CalciMedica, Inc. (the Board of Directors or Board) for use at the Companys 2024 Annual Meeting of Stockholders (the Annual Meeting) to be held virtually at www.proxydocs.com/CALC on Tuesday, August 27, 202

View Full Filing

View this DEF 14A filing on SEC EDGAR